Dr. Culver is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 800-223-2273
Education & Training
Cleveland Clinic FoundationFellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2003- Cleveland Clinic FoundationResidency, Internal Medicine, 1997 - 2000
Ohio University Heritage College of Osteopathic Medicine in AthensClass of 1996
Certifications & Licensure
OH State License 2000 - 2025- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Clinical Trials
- STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2012 Jul 16
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
- Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis Start of enrollment: 2014 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 12 citationsWhole lung lavage for lipoid pneumonia.Chris Lau, Basem Abdelmalak, Carol Farver, Daniel A. Culver
Thorax. 2016-06-10 - 214 citationsPD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 productionLindsay J. Celada, Jonathan A. Kropski, Jose D. Herazo-Maya, Weifeng Luo, Amy Creecy
Science Translational Medicine. 2018-09-26 - 216 citationsERS clinical practice guidelines on treatment of sarcoidosisRobert P. Baughman, Dominique Valeyre, Peter Korsten, Alexander G. Mathioudakis, Wim A. Wuyts
The European Respiratory Journal. 2021-06-17
Press Mentions
aTyr Pharma’s Fusion Protein Achieves Consistent Dose Response in Pulmonary Sarcoidosis TrialSeptember 16th, 2021- aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate UpdateAugust 10th, 2021
- Confused over the COVID-19 Third Shot Debate? Here’s What Cleveland Doctors SayJuly 19th, 2021
- Join now to see all
Grant Support
- Matrix Metalloproteinases And PPAR Gamma In SarcoidosisNational Heart, Lung, And Blood Institute2005–2009
- Matrix Metalloproteinases And PPAR Gamma In SarcoidosisNational Center For Research Resources2007
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
